Floatz logo

Florbetaben

Monoclonal Gammopathy of Undetermined Significance (MGUS)

University of ZurichSmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Monoclonal Gammopathy of Undetermined Significance (MGUS) cohort.

Asset / SponsorPhaseRating
Dfn-15
National Cancer Institute (NCI)
Phase 2B
Metformin
Dana-Farber Cancer Institute
Phase 2CCC
Linvoseltamab
Regeneron Pharmaceuticals
Phase 2CCC
Isatuximab
Assistance Publique - Hôpitaux de Paris
Phase 2CCC
Tetanus-Cmv Fusion Peptide Vaccine
City of Hope Medical Center
Phase 1CC

View all 13 →

Same molecule, other indications

Florbetaben is also rated in:

Cardiac AmyloidosisDormant
BBB
Indicative ·
73 / 100
View asset →
Alzheimer diseaseDormant
BBB
Indicative ·
72 / 100
View asset →
Amyloid Beta-ProteinDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →